You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

CLINICAL TRIALS PROFILE FOR METHADONE HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for methadone hydrochloride

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Formulation NCT00505583 ↗ Study Evaluating Oral MOA-728 in Subjects on Methadone Therapy Withdrawn Bausch Health Americas, Inc. Phase 1 2007-07-01 To evaluate the effects of single oral doses of MOA-728 compared to a positive control in subjects on methadone therapy.
New Formulation NCT00505583 ↗ Study Evaluating Oral MOA-728 in Subjects on Methadone Therapy Withdrawn Valeant Pharmaceuticals International, Inc. Phase 1 2007-07-01 To evaluate the effects of single oral doses of MOA-728 compared to a positive control in subjects on methadone therapy.
New Formulation NCT00640159 ↗ Tolerability and Efficacy of Switch From Oral Selegiline to Orally Disintegrating Selegiline (Zelapar) in Patients With Parkinson's Disease Completed Baylor College of Medicine Phase 4 2007-01-01 Parkinson's disease (PD) is a progressive neurodegenerative disease. Symptomatic therapy is primarily aimed at restoring dopamine function in the brain. Oral selegiline in conjunction with L-dopa has been a mainstay of therapy for PD patients experiencing motor fluctuations for many years. The mechanisms accounting for selegiline's beneficial adjunctive action in the treatment of PD are not fully understood. Inhibition of monoamine oxidase (MAO) type B (MAO-B) activity is generally considered to be of primary importance. Oral selegiline has low bio-availability and is typically dosed BID, for a total of 5-10 mg daily. Recently, the FDA approved a new orally disintegration tablet (ODT) formulation of selegiline, called ZelaparTM. This new formulation utilizes Zydis technology to dissolve in the mouth, with absorption through the oral mucosa, thereby largely bypassing the gut and avoiding first pass hepatic metabolism. This allows more active drug to be delivered at a lower dose. Consequently, Zelapar is dosed once-daily, up to 2.5 mg per day. There are no empirical data indicating whether the use of the new approved formulation of selegiline ODT (Zelapar) is superior or preferred by patients compared to traditional oral selegiline. It is believed that clinical efficacy will be preserved or enhanced, by delivering more active drug, with improved patient preference for the ODT formulation due to the once-daily dosing . The effectiveness of orally disintegrating selegiline as an adjunct to carbidopa/levodopa in the treatment of PD was established in a multicenter randomized placebo-controlled trial (n=140; 94 received orally disintegrating selegiline, 46 received placebo) of three months' duration. Patients randomized to orally disintegrating selegiline received a daily dose of 1.25 mg for the first 6 weeks and a daily dose of 2.5 mg for the last 6 weeks. Patients were all treated with levodopa and could additionally have been on dopamine agonists, anticholinergics, amantadine, or any combination of these during the trial. At 12 weeks, orally disintegrating selegiline-treated patients had an average of 2.2 hours per day less "OFF" time compared to baseline. Placebo treated patients had 0.6 hours per day less "OFF" time compared to baseline. These differences were significant (p < 0.001). Adverse events were very similar between drug and placebo.
New Indication NCT01189214 ↗ Psychopharmacotherapy in Multiple Substances Abuse Completed National Institutes of Health (NIH) Phase 3 2009-03-01 Add-on of memantine or placebo treatment will proceed in a double-blinded fashion for 12 weeks after adjusted methadone dose. During the study, the investigators will evaluate treatment response and adverse effect from multiple dimensions to elucidate the therapeutic effect of add-on memantine on addictive behaviors. It will also explore the possible advantage of this treatment on social re-adaptation and psychopathogenesis of opioid dependence.
New Indication NCT01189214 ↗ Psychopharmacotherapy in Multiple Substances Abuse Completed National Cheng-Kung University Hospital Phase 3 2009-03-01 Add-on of memantine or placebo treatment will proceed in a double-blinded fashion for 12 weeks after adjusted methadone dose. During the study, the investigators will evaluate treatment response and adverse effect from multiple dimensions to elucidate the therapeutic effect of add-on memantine on addictive behaviors. It will also explore the possible advantage of this treatment on social re-adaptation and psychopathogenesis of opioid dependence.
OTC NCT02137213 ↗ Feasibility Study of Oral Naloxone for Treatment of Methadone-induced Constipation Completed Academic Health Science Centres Phase 2 2014-08-01 At least 30% of patients receiving methadone maintenance therapy (MMT) are suffering from constipation that often affects effectiveness of MMT and increases its impact on health care system. Existing treatments include several over-the-counter medications which do not target the pathobiological basis of opioid-induced constipation and have limited effectiveness. At the same time well-known medication, naloxone, was already shown to help with constipation in patients receiving methadone for chronic pain, but was never tried in patients receiving methadone for opioid dependence. This study is aimed to try naloxone for treatment of opioid-induced constipation in MMT settings. The investigators will enroll 20 patients receiving MMT and suffering from opioid-induced constipation. The study has a crossover design - all patients will receive one week of their regular methadone doses and one week of their regular methadone doses with naloxone added. Normal saline will be added to methadone-only formulations as placebo. Order of the weeks will be chosen randomly. Both subjects and investigators will be blinded to the study condition (i.e. whether naloxone or normal saline is added to methadone preparation on a given week). Primary hypothesis: Patients receiving combination of oral methadone/naloxone in ratio 50:1 will have less severe symptoms of constipation compared to those receiving methadone only. Secondary hypothesis: Addition of oral naloxone to methadone in a ratio 50:1 will not cause clinically significant opioid withdrawal symptoms.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for methadone hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000200 ↗ Cocaine Effects in Humans: Physiology and Behavior - 1 Completed Columbia University Phase 2 1997-01-01 The purpose of this study is to compare the effects of buprenorphine or methadone maintenance on cocaine taking and on the physiological and subjective effects of cocaine, including cocaine craving, in opiate-dependent cocaine users.
NCT00000200 ↗ Cocaine Effects in Humans: Physiology and Behavior - 1 Completed National Institute on Drug Abuse (NIDA) Phase 2 1997-01-01 The purpose of this study is to compare the effects of buprenorphine or methadone maintenance on cocaine taking and on the physiological and subjective effects of cocaine, including cocaine craving, in opiate-dependent cocaine users.
NCT00000205 ↗ Buprenorphine Maintenance Protocol - 1 Completed National Institute on Drug Abuse (NIDA) Phase 3 1990-10-01 The purpose of this study is to compare the efficacy of buprenorphine versus methadone.
NCT00000205 ↗ Buprenorphine Maintenance Protocol - 1 Completed University of California, Los Angeles Phase 3 1990-10-01 The purpose of this study is to compare the efficacy of buprenorphine versus methadone.
NCT00000206 ↗ Clinical Rescue Protocol - 2 Completed National Institute on Drug Abuse (NIDA) Phase 2 1991-04-01 The purpose of this study is to detect increasing medication dose results in heroin cessation for patients still using, to determine if decreasing medication dose in patients unable to tolerate medication dose increases retention, and to determine if blood levels of methadone or buprenorphine correlate with clinical response.
NCT00000206 ↗ Clinical Rescue Protocol - 2 Completed University of California, Los Angeles Phase 2 1991-04-01 The purpose of this study is to detect increasing medication dose results in heroin cessation for patients still using, to determine if decreasing medication dose in patients unable to tolerate medication dose increases retention, and to determine if blood levels of methadone or buprenorphine correlate with clinical response.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for methadone hydrochloride

Condition Name

Condition Name for methadone hydrochloride
Intervention Trials
Opioid-Related Disorders 35
Opioid Dependence 32
Pain 32
Opioid Use Disorder 18
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for methadone hydrochloride
Intervention Trials
Opioid-Related Disorders 129
Substance-Related Disorders 42
Pain, Postoperative 36
Disease 29
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for methadone hydrochloride

Trials by Country

Trials by Country for methadone hydrochloride
Location Trials
United States 362
Canada 31
Brazil 10
Norway 9
Germany 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for methadone hydrochloride
Location Trials
New York 45
Maryland 40
California 32
Connecticut 21
Illinois 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for methadone hydrochloride

Clinical Trial Phase

Clinical Trial Phase for methadone hydrochloride
Clinical Trial Phase Trials
Phase 4 85
Phase 3 56
Phase 2/Phase 3 12
[disabled in preview] 150
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for methadone hydrochloride
Clinical Trial Phase Trials
Completed 217
Recruiting 41
Not yet recruiting 31
[disabled in preview] 67
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for methadone hydrochloride

Sponsor Name

Sponsor Name for methadone hydrochloride
Sponsor Trials
National Institute on Drug Abuse (NIDA) 103
Yale University 28
Johns Hopkins University 22
[disabled in preview] 28
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for methadone hydrochloride
Sponsor Trials
Other 475
NIH 134
Industry 72
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.